1015 related articles for article (PubMed ID: 23021878)
21. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
[TBL] [Abstract][Full Text] [Related]
23. [Short-term efficacy of anti-IgE monoclonal antibody in patients with recurrent chronic rhinosinusitis with nasal polyps combined with asthma].
Shen S; Lou HF; Yan B; Wang Y; Cao FF; Xiong W; Wang CS; Zhang L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 Oct; 56(10):1035-1041. PubMed ID: 34666463
[No Abstract] [Full Text] [Related]
24. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
25. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
[TBL] [Abstract][Full Text] [Related]
26. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
[TBL] [Abstract][Full Text] [Related]
27. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
29. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of omalizumab in the treatment of nasal polyps.
Vennera Mdel C; Picado C; Mullol J; Alobid I; Bernal-Sprekelsen M
Thorax; 2011 Sep; 66(9):824-5. PubMed ID: 21109700
[No Abstract] [Full Text] [Related]
31. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
[TBL] [Abstract][Full Text] [Related]
32. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.
Hoshino M; Ohtawa J
Respiration; 2012; 83(6):520-8. PubMed ID: 22236804
[TBL] [Abstract][Full Text] [Related]
33. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.
Berger W; Gupta N; McAlary M; Fowler-Taylor A
Ann Allergy Asthma Immunol; 2003 Aug; 91(2):182-8. PubMed ID: 12952113
[TBL] [Abstract][Full Text] [Related]
35. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis.
Kim DH; Park KY; Kim BJ; Kim MN; Mun SK
Clin Exp Dermatol; 2013 Jul; 38(5):496-500. PubMed ID: 23083013
[TBL] [Abstract][Full Text] [Related]
36. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
[TBL] [Abstract][Full Text] [Related]
37. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
38. Omalizumab in the treatment of asthma.
Tan R; Corren J
Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
[TBL] [Abstract][Full Text] [Related]
39. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
Shitrit D; Talker O; Metabichek A; Yaakovi I
Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
[TBL] [Abstract][Full Text] [Related]
40. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]